PAK1 and cancer: The current study provides supportive evidences for the potential application of IPA-3 in HCC treatment and the specificity of IPA-3 in targeting PAK1, suggesting that IPA-3 is a potential therapeutic target for the treatment of HCC and may be more effective on the advanced cancers.